A blood DNA result and an imaging result can seem to disagree because they sample different material, regions, times and signals. A mismatch is a question to resolve, not a verdict on either test.
A circulating tumour DNA (ctDNA) assay looks for tumour-associated features in a finite sample of cell-free DNA. How much tumour DNA reaches the sampled blood varies between lesions, and recovery, background DNA, the features tracked and the assay's detection limit all shape the call. Imaging measures a defined region through a physical signal. Magnetic resonance imaging (MRI) of the breast can report contrast enhancement or the volume of enhancing tissue, which is not a direct count of viable cancer cells. The two tests can therefore differ without either being wrong, and neither automatically replaces the other.
They can also share information. In Magbanua and colleagues' pilot of 84 women having neoadjuvant chemotherapy for early breast cancer, ctDNA concentration was correlated with MRI functional tumour volume at all four time points, with Spearman correlations of 0.42 to 0.49, and patients with detectable ctDNA had a higher median volume. Agreement was partial, and adding ctDNA early in treatment to volume-based prediction of pathological complete response gave only a numerical gain that was not statistically significant. ctDNA positivity after treatment added significantly to volume for predicting distant recurrence and death. A mismatch calls for checking dates, assay limits, the imaged region and the exact finding. It does not by itself show a false test or hidden metastatic disease.
Showing the technology this term belongs to: Liquid biopsy (ctDNA).
Shares Circulating tumour DNA fraction (and what a negative plasma result means), Cell-free DNA (cfDNA), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA) and the tags biomarker, measurement.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA) and the tags biomarker, measurement.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Cell-free DNA (cfDNA), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag biomarker.
Shares Circulating tumour DNA fraction (and what a negative plasma result means), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA) and the tag biomarker.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Cell-free DNA (cfDNA), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/